Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 468.29 USD -0.2% Market Closed
Market Cap: 120.6B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

25.1
Current
19.4
Median
4.6
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
25.1
=
Enterprise Value
113B USD
/
EBITDA
4.5B USD
All Countries
Close
EBITDA Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 17.3
25.1
43%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 873 N/A
US
Abbvie Inc
NYSE:ABBV
15.1
29%
US
Amgen Inc
NASDAQ:AMGN
16.5
62%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.6 N/A
AU
CSL Ltd
ASX:CSL
20.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -106 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -234.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
85.6
2-Years Forward
EV/EBITDA
19.7
3-Years Forward
EV/EBITDA
17.4

See Also

Discover More